Not for the 'Faint of Heart' | GenomeWeb

Diagnostics are a tough business, writes life sciences venture capitalist Bruce Booth.

And he should know — he's currently in the process of unwinding cancer diagnostics company On-Q-Ity, an investment by his firm, Atlas Ventures, that didn't quite work out.

The reading public is the beneficiary of Booth's loss, though, as he performs a post-mortem of sorts, looking at what went wrong.

Among the lessons learned:

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Patent Representation

Such High Hopes

Just the One, Really

This Week in PLOS

Best Candidates

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.